title: The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor.
abstract: The aim of this study was to look at the impact of the number of sites with tumour involvement on outcome for patients with stage IIIA endometrioid-type endometrial carcinoma.
  
  
  METHODS
  141 patients stage IIIA were included. A central histopathological review was performed. Patients staged solely on the presence of a positive peritoneal washing were excluded. Follow-up ranged from 2 to 217 months with a median of 43 months. Endpoints of the study were locoregional recurrence rates, distant metastasis-free survival (DMFS), disease-free survival (DFS) and disease-specific survival (DSS).
  
  
  RESULTS
  In multivariate analyses the number of involved sites showed to be the only independent significant variable for DMFS, DFS, and DSS with a Hazard Ratio of 2.1, 2.2, and 2.2, respectively. The DSS was significantly related to the number of involved sites, with a 5-year DSS of 70.4% for one site, 42.8% for two sites, and 43.9% for three sites, respectively (p=0.001).
  
  
  CONCLUSIONS
  The number of involved sites outside the corpus uterine for stage IIIA seems to be a strong negative prognostic factor for stage IIIA endometrial carcinoma.
authors.affiliation: Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, The Netherlands. j.jobsen@mst.nl
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Jobsen
authors.forename: Lambert Naudin
authors.initials: LN
authors.lastname: ten Cate
authors.forename: Marnix L M
authors.initials: ML
authors.lastname: Lybeert
authors.forename: Elzbieta M
authors.initials: EM
authors.lastname: van der Steen-Banasik
authors.forename: Astrid
authors.initials: A
authors.lastname: Scholten
authors.forename: Job
authors.initials: J
authors.lastname: van der Palen
authors.forename: Annerie
authors.initials: A
authors.lastname: Slot
authors.forename: Marika C Stenfert
authors.initials: MC
authors.lastname: Kroese
authors.forename: Eltjo M J
authors.initials: EM
authors.lastname: Schutter
authors.forename: Sabine
authors.initials: S
authors.lastname: Siesling
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018269:Carcinoma, Endometrioid / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging